|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Searle_Pharmaceuticals
|
|
gptkbp:activities
|
Inhibits proton pump in gastric parietal cells
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1995
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:brand
|
gptkb:Lansoprazole_Delayed-Release_Capsules
gptkb:Prevacid
Zoton
|
|
gptkbp:class
|
Proton pump inhibitor
|
|
gptkbp:clinical_trial
|
Phase IV
Phase III
|
|
gptkbp:contraindication
|
Pregnancy category C
Hypersensitivity to lansoprazole
|
|
gptkbp:discontinued
|
gptkb:Prevacid_Solu_Tab
|
|
gptkbp:dosage_form
|
15 mg once daily
30 mg once daily
60 mg for Zollinger-Ellison syndrome
|
|
gptkbp:form
|
Tablets
Capsules
Injectable solution
Oral suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lansoprazole
|
|
gptkbp:ingredients
|
C17 H19 N3 O2 S
|
|
gptkbp:interacts_with
|
gptkb:Clopidogrel
gptkb:Methotrexate
gptkb:Digoxin
gptkb:Warfarin
Antiretrovirals
|
|
gptkbp:is_atype_of
|
A02 B C03
|
|
gptkbp:is_available_on
|
Generic medication
|
|
gptkbp:is_used_for
|
gptkb:Zollinger-Ellison_syndrome
Peptic ulcer disease
Gastroesophageal reflux disease (GERD)
|
|
gptkbp:lifespan
|
1.5 hours
|
|
gptkbp:manager
|
Intravenous
Oral
|
|
gptkbp:metabolism
|
Hepatic
|
|
gptkbp:nutritional_value
|
97%
|
|
gptkbp:products
|
gptkb:Dexlansoprazole
gptkb:Rabeprazole
gptkb:Esomeprazole
gptkb:Pantoprazole
gptkb:Omeprazole
|
|
gptkbp:side_effect
|
gptkb:Nausea
Diarrhea
Headache
Constipation
Abdominal pain
|
|
gptkbp:storage
|
Store at room temperature
Protect from moisture
|
|
gptkbp:type_of
|
103577-45-3
|